Beta-HPV association with SCC tops dermatology reads for week

Study results showing that beta-genus HPV was a significant risk factor for cutaneous squamous cell carcinoma in healthy people was among the most-read articles of the past week on Healio.com/Dermatology.

Other widely read articles included findings that menopausal hormone therapy increased risk for basal cell carcinoma and Health Canada’s approval of Stelara for adolescents with psoriasis:

Beta-HPV associated with cutaneous squamous cell carcinoma

Beta-genus HPV was a significant risk factor for cutaneous squamous cell carcinoma in healthy people, according to study results published in JAMA Dermatology.

Researchers conducted a systematic literature search of the Medline and Embase databases for human studies through June 18, 2014. Read more

Early treatment may prevent skin necrosis related to nose augmentation with hyaluronic acid

Augmentation of the nose and nasolabial fold with hyaluronic acid may lead to impending nasal skin necrosis, according to study results.

Researchers in China reviewed medical records from between 2008 and 2014 to identify 20 patients (age range, 21 to 52 years; 90% women) who experienced skin necrosis associated with nose and or nasolabial fold augmentation with only hyaluronic acid fillers. Read more

Menopausal hormone therapy may increase risk for basal cell carcinoma

Menopausal hormone therapy increased risk for basal cell carcinoma, especially among women with an older age at menopause, according to the results of a nationwide cohort study.

These women may require more frequent skin cancer screening, according to the researchers. Read more

Health Canada approves Stelara for treating psoriasis in adolescents

Health Canada has approved Stelara for treating moderate-to-severe plaque psoriasis in adolescents who are intolerant to or have been inadequately controlled by other systemic therapies or phototherapies, according to a press release from Janssen.

The approval of Stelara (ustekinumab) is based on data from the phase 3 CADMUS study that measured the efficacy and safety of ustekinumab in patients aged 12 to 17 years with moderate-to-severe plaque psoriasis, according to the release. Read more

Allergan expands neurotoxin pipeline with Anterios acquisition

Allergan announced in a press release the acquisition of Anterios, a biopharmaceutical company developing a next generation neurotoxin delivery system and botulinum toxin-based prescription products.

Allergan agreed to an upfront payment of $90 million, and commercialization milestone payments related to NDS, Anterios’ proprietary platform delivery system that allows for targeted delivery of neurotoxins through the skin without an injection, according to the release. Read more